Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Dolutegravir Passes Late Pregnancy Test

Publish date:: April 12, 2019

Key clinical point: Faster acting integrase inhibitors have the potential to accelerate reduction of viral load.

Major finding: Three-quarters of patients achieved viral load less than 50 copies/mL at delivery with dolutegravir, compared with 43% receiving efavirenz.

Study details: A randomized, controlled trial (n = 268).

Disclosures: The study was funded by the University of Liverpool. Dr. Khoo reported consulting for and receiving research funding from ViiV.

Citation:

Khoo S et al. CROI 2019, Abstract 40 LB.

This Week's Must Reads

Repeat LTBI Testing Best in Patients Taking Biologics With New Risk Factors,

Perioperative Antirheumatic Drug Use Does Not Impact Postsurgery Infection Rate in RA Patients,

A triple-antibiotic cure for Crohn’s disease?,

Health Care: More Uninsured As Insurance Costs Grow Faster,

CDC finds that efforts to reduce new HIV infections have stalled,

Must Reads in HIV

CDC finds that efforts to reduce new HIV infections have stalled,

ART traces in donor samples show risk to blood supply,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Novel Translocation Inhibitor Shows Efficacy in Treatment-Naive HIV-1–Infected Adults,

HCV coinfection adds to cardiovascular risk in HIV-infected patients,